Trial design and participants
malignancy, fracture, THA
DEEP VEIN THROMBOSIS, SEVERE DYSPLASIA, SECONDARY OSTEOARTHRITIS, SEVERE OBESITY
Inclusion criteria were: elective primary THA due to primary or secondary osteoarthritis. Exclusion criteria were: age < 18 years or > 90 years, severe dysplasia of the hip, use of other prosthetic components than those mentioned below, severe obesity (body mass index (BMI) > 40 kg/m2), malignancy, condition following deep vein thrombosis, therapeutic anticoagulation, immobility with preoperative walking distance < 100 m with forearm crutch or wheeled walker, a prior fracture within the surgical region, open pre-surgery, simultaneous participation in another study or refusal by the subject. The study was approved by the local Ethics Committee (approval number 19-1308-101). The study was applied in accordance with the ethical standards of the Declaration of Helsinki 1975. No changes after trial commencement were made with regard to course of the study. 6 patients withdrew approval after randomization but before data acquisition with the justification, that the extent of data evaluation is too extensive. No patient died within the study period. 194 patients were finally evaluated. The flowchart (Fig. 